ClinicalTrials.gg
RecruitingNCT07588568ATUNEUpdated Oct 6, 2026

A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis

A Phase 2 interventional study of Upadacitinib 30mg Dose and Upadacitinib Matching Placebo in EoE, Eosinophilic Esophagitis and Eosinophilic Esophagitis (EoE), sponsored by University of North Carolina, Chapel Hill. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University of North Carolina, Chapel Hill · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 6, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 165 studies in Eosinophilic Esophagitis with a site in United States — 23 open to participants now, 40 under way, 3 of them phase 3. Eosinophilic Esophagitis · United States.

Planned enrollment
46th of 111
52 · median 36
Started
2026
with 4 others
Phase 2
30 of 165
3 open now
Primary completion
2030-02
later than 35 of 39 live
Registered
164th of 165
by date
Lead sponsor
9 of 165
University of North Carolina, Chapel Hill

Among the 165 studies in Eosinophilic Esophagitis with a site in United States, this one is the 46th largest by planned enrollment of the 111 interventional ones that give a count, is one of 5 that started in 2026, is one of 30 in phase 2, reaches primary completion later than 35 of the 39 other live ones, and was the 164th registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

23 of the 165 studies in Eosinophilic Esophagitis with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Eosinophilic Esophagitis studies recruiting now, 13 (30%) set no upper age limit and 27 (63%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Eosinophilic Esophagitis with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE).

The main question it aims to answer are:

- Does upadacitinib in addition to topical corticosteroids help reduce EoE disease activity?

Participants will:

  • Take upadacitinib or placebo every day for 12 weeks, followed by 12 weeks of upadacitinib
  • Fill out surveys and answer health questions
  • Visit the clinic every 4 weeks for checkups and tests
Read the detailed description

The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE). This study has different parts. In the first part of the study, some people get the real medicine and some people get a "placebo," which is a pill with no medicine in it. These groups are decided by chance. In the second part of the study, everyone gets the real medication.

After screening, qualified participants will be randomly assigned to receive either the medicine or placebo and start taking the medicine. Participants will come to the clinic for a visit every 4 weeks and have a physical exam, blood tests, answer health questions, and complete surveys.

The first 12-weeks of the study treatment are "blinded," meaning participants and the study team won't know who gets the real medicine and who gets the placebo. The next 12 weeks are "open-label," meaning everyone gets upadacitinib. After each 12-week part, participants will have an upper endoscopy (esophagogastroduodenoscopy; EGD) to check on EoE disease activity.

30 days after the final EGD, participants will have a final checkup.

03

Conditions studied

  • EoE
  • Eosinophilic Esophagitis
  • Eosinophilic Esophagitis (EoE)

Keywords

  • Eosinophilic Esophagitis
  • EoE
  • upadacitinib
  • rinvoq
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-65 years.
  2. Diagnosis of EoE per 2018 AGREE consensus guidelines.
  3. Currently using topical (TCS) for EoE treatment (either swallowed budesonide, ≥2mg total daily dose or swallowed fluticasone, ≥1760 mcg total daily dose) for at least 8 weeks (prior to the screening endoscopy) and willing to remain on the same TCS treatment with no changes to regimen throughout the study.
  4. Have active esophageal eosinophilia (peak eosinophil count ≥15 eos/hpf [eosinophils per high power field]) as measured during the screening endoscopy despite ongoing therapy with TCS.
  5. Have active symptoms of esophageal dysfunction attributed to EoE (such as trouble swallowing, heartburn, reflux, vomiting, chest pain, painful swallowing, abdominal pain, malnutrition, etc.) in the 4 weeks prior to the screening endoscopy.
  6. Willing to continue all current EoE treatments (including medications such as proton pump inhibitors (PPIs), diet elimination, etc.) throughout participation in the study.
  7. Able to read, comprehend, and sign consent form.
  8. Ability to take oral medication (swallow a pill) and be willing to adhere to the study regimen (follow dosing instructions and complete study procedures).

Exclusion criteria

Exclusion Criteria:

  1. Use of systemic (such as prednisone or methylprednisolone) within 4 weeks of the screening endoscopy.
  2. Use of dupilumab (dupixent) within 3 months of the screening endoscopy.
  3. Use of estrogen (including estrogen-containing and other hormonal treatments) within 30 days of screening.
  4. Previous esophageal resection.
  5. Medical instability making it unsafe to perform an upper endoscopy.
  6. At the Screening / Baseline or Enrollment Visit, meeting any of the following conditions:

    6.1. Two or more prior episodes of herpes zoster (shingles), or one or more episodes of disseminated herpes zoster;

    6.2. One or more prior episodes of disseminated herpes simplex (including eczema herpeticum);

    6.3. (HIV) infection, defined as confirmed positive anti-HIV antibody (HIV Ab) test or a positive HIV Ab/Ag test;

    6.4. Active tuberculosis (TB) or latent TB, or meet TB exclusionary parameters;

    6.5. Active infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days, or oral/intramuscular anti-infectives within 14 days prior to the visit;

    6.6. Active diverticulitis within the past 3 months;

    6.7. Chronic recurring infection and/or active viral infection that, based on the investigator's clinical assessment, makes the participant an unsuitable candidate for the study;

    6.8. COVID-19 infection: In participants who tested positive for COVID-19, at least 5 days must have passed between a COVID-19 positive test result and the visit of asymptomatic participants. Participants with mild/moderate COVID-19 infection can be enrolled if fever is resolved without use of antipyretics (fever reducers such as ibuprofen, aspirin, and paracetamol) for 24 hours and other symptoms improved, or if 5 days have passed since the COVID-19 positive test result (whichever comes last). Participants may be rescreened if deemed appropriate by the investigator based upon the participant's health status.

    6.9. (HBV) and (HCV) screening values that meet the following criteria at the most recent testing prior to the first dose of study drug:

    6.9.1. HBV: hepatitis B surface antigen (HBs Ag) positive (+) test or detectable HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) qualitative test for participants who are hepatitis B core antibody (HBc Ab) positive (+);

    6.9.2. HCV: detectable HCV ribonucleic acid (RNA) in any participant with anti-HCV antibody (HCV Ab).

  7. At the Screening / Baseline or Enrollment visit, any of the following medical diseases or disorders:

    7.1. Prior history of

    • cerebrovascular accident (stroke),
    • myocardial infarction (heart attack),
    • coronary stenting,
    • coronary bypass surgery (heart bypass surgery),
    • or thrombotic events including deep venous thrombosis (DVT) and pulmonary embolism (PE);

    7.2. History of an organ transplant which requires continued ;

    7.3. History of an allergic reaction or significant sensitivity to constituents of the study drug (and its ) and/or other products in the same class;

    7.4. History of GI perforation (other than due to appendicitis or mechanical injury), diverticulitis, or significantly increased risk for GI perforation per investigator judgment;

    7.5. Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery; participants with a history of gastric banding/segmentation (such as Lap Band or Realize Band) are not excluded;

    7.6. History of except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix;

    7.7. Current uncontrolled hypertension defined as a confirmed systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg;

    7.8. Known inherited or acquired conditions that predispose to hypercoagulability;

    7.9. Current or past smokers;

    7.10. In patients 50 years of age and older:

    • High-density lipoprotein (HDL) cholesterol level of \<40mg per deciliter,
    • Diabetes mellitus,
    • Family history of premature coronary heart disease,
    • Extraarticular rheumatoid arthritis.

    7.11. Severe hepatic impairment (i.e., C cirrhosis).

  8. Participants of who do not meet the following:

    8.1. Participants must not have a positive serum pregnancy test (blood test) at the Screening Visit and must have a negative urine pregnancy test at the Enrollment visit prior to the first dose of study drug.

    8.2. Participants with an abnormal or inconclusive serum pregnancy test at Screening must have absence of clinical suspicion of pregnancy or other pathological causes and a serum pregnancy test ≥ 3 days later to document continued lack of a positive result.

    8.3. Participants with a urine pregnancy test at the Enrollment visit that is borderline or ambiguous must have a serum pregnancy test performed. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.

    8.4. Participants of childbearing potential who are not able and/or willing to practice at least 1 protocol-specified method of birth control that is highly effective throughout participation in the study (from Screening through at least 30 days after the last dose of study drug. Use of estrogen-containing contraception is not allowable. Participants of non-childbearing potential do not need to use birth control.

  9. Participants who are pregnant, breastfeeding, or considering becoming pregnant during the study and for 30 days after the last dose of study drug.
  10. Participants who received treatment with any drug of chemical or biologic nature within 30 days or five half-lives (whichever is longer) prior to the screening endoscopy or who are currently enrolled in another interventional clinical study.
  11. Participants with systemic use of known strong cytochrome P450 3A () inhibitors or strong CYP3A inducers within 30 days or five half-lives (whichever is longer) of the screening endoscopy through the end of study participation: Herbal therapies and other traditional medicines with unknown effect on CYP3A taken systemically are prohibited within 30 days prior to the screening endoscopy and throughout the study. Herbal therapies and other traditional medicines are defined as any herbal formulation intended to treat or prevent health problems and may include supplements based on which herbs the participant is taking.
  12. Participants who have received any with replicating potential within 30 days prior to the first dose of study drug or have expected need of vaccination with any live vaccine with replicating potential during study participation including at least 30 days after the last dose of study drug. Live vaccines that are incapable of replicating are permitted.
  13. Screening laboratory values that meet the following criteria at the most recent testing prior to the first dose of study drug:

    13.1. Serum (AST) > 2 × (ULN); 13.2. Serum alanine transaminase (ALT) > 2 × ULN; 13.3. Estimated (GFR) by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula \< 30 mL/min/1.73 m2; 13.4. Total white blood cell (WBC) count \< 2,500/µL; 13.5. (ANC) \< 1,200/µL; 13.6. count \< 100,000/µL; 13.7. Absolute lymphocyte count \< 750/µL; 13.8. \< 9 g/dL.

  14. Known allergic reaction, significant sensitivity, or intolerance to Janus kinase (JAK) inhibitors or their components
  15. History of or current medical or psychiatric conditions or any other reason that in the opinion of the Investigator would interfere with the participant's participation in this study, would place the participant at risk by participating in the study or would make the participant an unsuitable candidate to receive study drug.
  16. Inability to read or understand English.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Upadacitinib 30mg

    Participants randomly assigned to this arm will receive the active drug for the entire 24 week treatment period. During the first 12 weeks, participants will receive blinded upadacitinib 30mg daily (meaning the participant and study team will not know which medication the participant receives) followed by open-label upadacitinib 30mg daily for 12 weeks.

    Drug: Upadacitinib 30mg Dose

  • Other
    Placebo, followed by Upadacitinib 30mg

    Participants randomly assigned to this arm will receive placebo for 12 weeks, followed by upadacitinib 30mg for 12 weeks. During the first 12 weeks, participants will receive blinded placebo daily (meaning the participant and study team will not know which medication the participant receives) followed by open-label upadacitinib 30mg daily for 12 weeks.

    Drug: Upadacitinib 30mg Dose · Other: Upadacitinib Matching Placebo

Interventions

  • DrugUpadacitinibStudies of UpadacitinibUpadacitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Upadacitinib 30mg oral tablet. Participants randomly assigned to receive upadacitinib will take upadacitinib 30mg daily throughout the study. Participants randomly assigned to receive placebo will receive upadacitinib for 12 weeks after completing the 12 week blinded treatment period.

    Also known as: RINVOQ, upadacitinib

  • OtherUpadacitinib Matching Placebo

    Oral tablet matching in size, shape, color, and taste to the study intervention (upadacitinib). Participants randomly assigned to receive placebo will receive upadacitinib matching placebo for 12 weeks, followed by a 12 week open label treatment period where all participants will receive upadacitinib 30mg.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Peak eosinophil count (measured in eos/hpf) after 12-weeks of treatment

    Peak eosinophil count (number of eosinophils per high power field (eos/hpf)) will be measured at 12-weeks post-treatment via esophageal biopsy during the study endoscopy. Eosinophil counts will be determined centrally by the study pathologist using a validated protocol.

    Time frame: At 12-weeks post-treatment

Secondary outcomes

  1. Key Secondary Outcome: Post-treatment EoE histologic scoring system (HSS) after 12-weeks of treatment

    The EoE Histologic Scoring System (EoEHSS) score ranges from 0-1, with higher scores indicating greater histologic severity. This study will compare both grade (most severe area) and stage (extent of involvement) parameters of the HSS. EoEHSS will be assessed centrally by the study pathologist.

    Time frame: At 12-weeks post-treatment

  2. Post-treatment EoE Endoscopic Reference Score (EREFS) after 12-weeks of treatment

    EREFS ranges from 0-9, with higher scores indicating greater endoscopic severity. EREFS will be assessed during endoscopy by the endoscopist.

    Time frame: At 12-weeks post-treatment

  3. Proportion of participants with histologic response (<15, ≤ 6, and ≤ 1 eos/hpf) after 12-weeks of treatment.

    Proportion (percentage) of participants who achieve histologic response at each threshold (\<15 eosinophils per high power field (eos/hpf), ≤ 6 eos/hpf, and ≤ 1 eos/hpf) after 12-weeks of treatment. All eosinophil counts will be performed centrally by the study pathologist.

    Time frame: 12-weeks post-treatment

  4. Mean change in dysphagia as measured by the EoE Symptom Activity Index (EEsAI) from baseline to 12-weeks post-treatment

    EEsAI is a validated patient-reported outcome instrument which measures symptoms of dysphagia over a 7-day recall period. EEsAI scores range from 0 to 100, with higher scores indicating more severe symptoms.

    Time frame: From screening/baseline to 12-weeks post-treatment

  5. Minimum esophageal diameter as measured using the Endoluminal Functional Lumen Imaging Probe (EndoFLIP) after 12-weeks of treatment

    EndoFLIP measures esophageal compliance and distensibility, and yields a measurement of the minimum esophageal diameter (in mm). This will be performed during endoscopy by the endoscopist.

    Time frame: At 12-weeks post-treatment

  6. Esophageal distensibility plateau as measured on EndoFLIP after 12-weeks of treatment

    EndoFLIP measures esophageal compliance and distensibility, and yields a measurement of the minimum esophageal diameter (in mm). This will be performed during endoscopy by the endoscopist.

    Time frame: At 12-weeks post-treatment

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — This study will adhere to the NIH Grant Policy on Sharing of Unique Research Resources including the Sharing of Biomedical Research Resources Principles and Guidelines for Recipients of NIH Grants and Contracts.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with University of North Carolina at Chapel Hill (UNC).

Access criteria: When data sharing is permitted, a Data Use Agreement (DUA) specifying the uses of such data to be shared must be in place before any data is shared. Requests can be submitted to the UNC Office of Industry Contracting for processing. The Principal Investigator must confirm that the DUA has been fully executed and IRB, IEC, or REB approval has been granted before sharing data. For further information on DUAs, please refer to the Data Use Agreement Guidance: https://osp.unc.edu/contracting/contracting/. Any questions about data sharing may be directed to the sponsor-investigator, Evan Dellon, at evan_dellon@med.unc.edu.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Feb 2030, 41 months after the start.

Of 24 phase 2 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's planned 41 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 15, 2026
StartActual
Sep 30, 2026was Oct 2026
Primary completionEst.
Feb 2030
CompletionEst.
Jun 2030
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 6, 2026
Sites
2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • University of North Carolina at Chapel Hill · Chapel Hill, United Statesno status→Recruiting
  • Duke University · Durham, United Statesno status→Not yet recruiting
Oct 6, 2026
Start date
Oct 2026→Sep 30, 2026 (actual)
Oct 6, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of North Carolina at Chapel Hill · Chapel Hill, United StatesContact h•••@med.unc.edu · •••2996→h•••@med.unc.edu · •••2996Contact j•••@med.unc.edu · •••4453→j•••@med.unc.edu · •••4453
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
    Show 2 sites
    • University of North Carolina at Chapel Hill · Chapel Hill, United Statesno status→Recruiting
    • Duke University · Durham, United Statesno status→Not yet recruiting
    Start date Oct 2026→Sep 30, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of North Carolina at Chapel Hill · Chapel Hill, United StatesContact h•••@med.unc.edu · •••2996→h•••@med.unc.edu · •••2996Contact j•••@med.unc.edu · •••4453→j•••@med.unc.edu · •••4453
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07588568
Responsible party
Sponsor
First posted
May 15, 2026
Start date
Sep 30, 2026
Primary completion
Feb 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Oct 6, 2026

Study contacts

Lindsay Cortright, MA
Contact
lindsay_cortright@med.unc.edu
919-445-4911
Susan Moist, MPH
Contact
susan_moist@med.unc.edu
919-918-5900
Evan S Dellon, MD, MPH
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion